Excelra mined patent literature to identify and structure antibody sequences, clones, targets, and binding affinity, creating a comprehensive dataset for AI/ML-driven drug discovery.
Public source
Publisher name
Public post
From scattered patent information to structured antibody intelligence. In our latest case study, Excelra mined patent literature to identify and structure antibody sequeโฆ
Company
Excelra
Where data means more
- Industry
- Data Infrastructure and Analytics
- Location
- NJ, US
- Company size
- 1,001โ5,000 employees
About Excelra
Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. ๐๐บ๐ฝ๐ผ๐๐ฒ๐ฟ๐ถ๐ป๐ด ๐๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป๐ ๐๐ถ๐๐ต ๐๐ ๐ฝ๐ฒ๐ฟ๐๐ถ๐๐ฒ Excelraโs interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. ๐๐ผ๐น๐น๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ถ๐๐ฒ ๐ฆ๐ผ๐น๐๐๐ถ๐ผ๐ป๐ ๐ณ๐ผ๐ฟ ๐๐ป๐ต๐ฎ๐ป๐ฐ๐ฒ๐ฑ ๐๐ฎ๐ฝ๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ถ๐ฒ๐ At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. ๐๐ฟ๐ผ๐บ ๐๐ต๐ฎ๐ผ๐ ๐๐ผ ๐๐น๐ฎ๐ฟ๐ถ๐๐: ๐ฆ๐๐ฟ๐๐ฐ๐๐๐ฟ๐ถ๐ป๐ด ๐๐ฎ๐๐ฎ We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. ๐๐ผ๐บ๐บ๐ถ๐๐๐ฒ๐ฑ ๐๐ผ ๐ฌ๐ผ๐๐ฟ ๐๐ผ๐ฎ๐น๐ Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. ๐ฅ๐ฒ๐ฑ๐ฒ๐ณ๐ถ๐ป๐ถ๐ป๐ด ๐๐ฟ๐๐ด ๐๐ฒ๐๐ฒ๐น๐ผ๐ฝ๐บ๐ฒ๐ป๐ ๐ง๐ผ๐ด๐ฒ๐๐ต๐ฒ๐ฟ Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.
See moreLatest activity
Latest activity from Excelra
7 signals
Research & Knowledge
Excelra published a blog exploring how advances in precision medicine, AI, multi-omics, and next-generation therapeutics are transforming dermatology and accelerating the shift toward more precise, personalized, and biology-driven solutions.
Products & Services
Excelra established a FAIR-aligned data platform connecting the mRNA R&D lifecycle to enable end-to-end traceability and faster, more informed decision-making.
Presence & Recognition
Excelra is sponsoring Lab of the Future Congress Europe 2026 taking place on September 22โ23 in Amsterdam.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
CAS
CAS published an analysis of 368,000+ global pharmaceutical patent filings showing that AI and ML applications now account for nearly 24% of patent filings up from just 9% in 2020.
Research & Knowledge
Sygnature Discovery
Sygnature Discovery published a Deloitte perspective on metadata architectures arguing that context is the foundation of an AI-ready R&D organization.
Research & Knowledge
Elucidata
Elucidata started a series called Target Discovery: Lessons from the Field to ask people who have run target discovery programs about what the work looks like on ground.
Research & Knowledge
RoukenBio
RoukenBio published a study in Nature Biotechnology by M Frank Erasmus et al. regarding artificial intelligence in silico affinity maturation and developable designs.
Research & Knowledge
Ardigen